Contracts › 75A50119C00055
75A50119C00055: This Contract Is to Advance the Development of Monovalent Vaccines for Prevention of Marburg Virus (MARV) and Sudan Ebolavirus (SUDV) Disease.
Awarded to Albert B. Sabin Vaccine Institute, Inc. (The) by Office of Assistant Secretary for Preparedness and Response.
$145.4Mobligated
$148.1Mpotential value
30 September 2027current end date
See modifications, all subcontractors and funding in FedSift →
| Contract | 75A50119C00055 |
|---|---|
| Awardee | Albert B. Sabin Vaccine Institute, Inc. (The) |
| Awarding agency | Office of Assistant Secretary for Preparedness and Response |
| Awarding office | BARDA - ASPR / DAAPPO / BARDA DCMA |
| NAICS | 541714 Research and Development in Biotechnology (Except Nanobiotechnology) |
| PSC | AN73 R&D- Medical: Specialized Medical Services (Advanced Development) |
| Place of performance | DC |
| Offers received | 3 |
| Period of performance | 26 September 2019 to 30 September 2027 |
| Potential end | 30 September 2027 |
| Estimated recompete solicitation | ~Q2 2027 (estimate, ~6 months before expiry) |
Source: USASpending.gov (FPDS), public federal procurement data, as the agency reported it. Our record updated 03 October 2026. The solicitation date is an estimate from the end date, not a posted date.
Other expiring 541714 contracts · All expiring contracts · USASpending record